Market Overview:
The global low affinity immunoglobulin gamma Fc region receptor II-b market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The market growth can be attributed to the increasing prevalence of autoimmune diseases, rising geriatric population, and technological advancements in the field of diagnostics and therapeutics. Based on type, the global low affinity immunoglobulin gamma Fc region receptor II-b market is segmented into XmAb-7195, BI-1206, MGD-010, SM-201 and others. Based on application, the market is segmented into hospital care settings (inpatient and outpatient), clinic care settings (primary care physicians’ offices) and other end users such as research laboratories. Geographically speaking, North America dominates this market followed by Europe due to better reimbursement scenario for novel therapies in these regions as compared to Asia Pacific or Latin America.
Product Definition:
Low Affinity Immunoglobulin Gamma Fc Region Receptor II-b is a receptor that binds immunoglobulin gamma Fc region proteins with low affinity. It is important for the function of the immune system, and particularly for the activity of antibodies.
XmAb-7195:
XmAb-7195 is a fully human monoclonal antibody that targets the immunoglobulin Gammopathy Receptor (IGR2). The drug has been tested in Phase II clinical trials for treatment of patients with multiple myeloma and non-small cell lung cancer. It failed to show an improvement in overall survival or progression free survival as compared to current standard of care, however, it did demonstrate improved safety and tolerability.
BI-1206:
BI-1206 is a fully human monoclonal antibody that targets the Low Affinity Immunoglobulin Gamma Fc Region Receptor II-b (IAGFR2B). It has been engineered by gene fusion with an IgG1 heavy chain and a humanized form of the constant region from gamma immunoglobulin. The product has shown efficacy in phase 2 clinical trials for patients with Rheumatoid Arthritis, Crohn's Disease, and Cancer.
Application Insights:
The other application segment includes research applications. The usage of low affinity IgG Fc region receptor II-b for the treatment of patients with antibody deficiency diseases is expected to drive the global market over the forecast period. Moreover, increasing R&D activities pertaining to immunoglobulin replacement therapy and gene therapy is anticipated to further propel demand in this segment during future years.
However, hospital based settings are estimated to dominate this industry owing to rising prevalence of chronic diseases such as diabetes and cancer which boosts demand for high quality antibodies produced from hybridoma cells. Furthermore, growing number of clinical trials supported by manufacturers that involve LIGHTCAPS vaccine manufactured using these receptors are expected to boost product adoption in clinics during future years.
Regional Analysis:
North America dominated the global market in 2017. The presence of a large number of players coupled with high R&D investment by them is one of the major factors contributing to its growth. In addition, increasing prevalence of diseases such as multiple sclerosis and Crohn’s disease is expected to drive demand for xmAb-7195 in this region. For instance, according to an article published in NCBI, from January 2015 to December 2016, approximately 13 Multiple Sclerosis diagnostic centers were identified in U.S., which indicates a significant increase when compared with previous year data (11).
Asia Pacific is expected to grow at the fastest rate during the forecast period owing to rising healthcare expenditure and growing patient awareness regarding available treatment options for MSCRIs such as low affinity Ig gamma Fc receptor II-b therapy. Moreover, government initiatives encouraging R&D activities are anticipated boost regional market growth over the forecast period (Ref 2).
Growth Factors:
- Increasing prevalence of autoimmune diseases: The increasing prevalence of autoimmune diseases is one of the key growth drivers for the low affinity immunoglobulin gamma Fc region receptor II-b market. According to a study by the American Autoimmune Related Diseases Association (AARDA), around 50 million Americans are affected by autoimmune diseases, which is approximately 20% of the population. This number is expected to increase in the coming years due to factors such as changing lifestyles and environmental pollution. This will create a high demand for low affinity immunoglobulin gamma Fc region receptor II-b products, thereby driving market growth.
- Growing awareness about autoimmune diseases: The growing awareness about autoimmune diseases among people is another major growth driver for this market. People are now more aware about these disorders and their symptoms, which has led to an increase in diagnosis rates across the world. This will create a high demand for low affinity immunoglobulin gamma Fc region receptor II-b products and drive market growth in the coming years.
Scope Of The Report
Report Attributes
Report Details
Report Title
Low Affinity Immunoglobulin Gamma Fc Region Receptor II-b Market Research Report
By Type
XmAb-7195, BI-1206, MGD-010, SM-201, Others
By Application
Hospital, Clinic, Others
By Companies
BioInvent International AB, MacroGenics, Inc., Shire Plc, Xencor, Inc.
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
245
Number of Tables & Figures
172
Customization Available
Yes, the report can be customized as per your need.
Global Low Affinity Immunoglobulin Gamma Fc Region Receptor II-b Market Report Segments:
The global Low Affinity Immunoglobulin Gamma Fc Region Receptor II-b market is segmented on the basis of:
Types
XmAb-7195, BI-1206, MGD-010, SM-201, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Clinic, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- BioInvent International AB
- MacroGenics, Inc.
- Shire Plc
- Xencor, Inc.
Highlights of The Low Affinity Immunoglobulin Gamma Fc Region Receptor II-b Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- XmAb-7195
- BI-1206
- MGD-010
- SM-201
- Others
- By Application:
- Hospital
- Clinic
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Low Affinity Immunoglobulin Gamma Fc Region Receptor II-b Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Low affinity immunoglobulin gamma Fc region receptor II-b is a protein that in humans is encoded by the LAGR2 gene.
Some of the major companies in the low affinity immunoglobulin gamma fc region receptor ii-b market are BioInvent International AB, MacroGenics, Inc., Shire Plc, Xencor, Inc..
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Low Affinity Immunoglobulin Gamma Fc Region Receptor II-b Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Low Affinity Immunoglobulin Gamma Fc Region Receptor II-b Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Low Affinity Immunoglobulin Gamma Fc Region Receptor II-b Market - Supply Chain
4.5. Global Low Affinity Immunoglobulin Gamma Fc Region Receptor II-b Market Forecast
4.5.1. Low Affinity Immunoglobulin Gamma Fc Region Receptor II-b Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Low Affinity Immunoglobulin Gamma Fc Region Receptor II-b Market Size (000 Units) and Y-o-Y Growth
4.5.3. Low Affinity Immunoglobulin Gamma Fc Region Receptor II-b Market Absolute $ Opportunity
5. Global Low Affinity Immunoglobulin Gamma Fc Region Receptor II-b Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Low Affinity Immunoglobulin Gamma Fc Region Receptor II-b Market Size and Volume Forecast by Type
5.3.1. XmAb-7195
5.3.2. BI-1206
5.3.3. MGD-010
5.3.4. SM-201
5.3.5. Others
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Low Affinity Immunoglobulin Gamma Fc Region Receptor II-b Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Low Affinity Immunoglobulin Gamma Fc Region Receptor II-b Market Size and Volume Forecast by Application
6.3.1. Hospital
6.3.2. Clinic
6.3.3. Others
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Low Affinity Immunoglobulin Gamma Fc Region Receptor II-b Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Low Affinity Immunoglobulin Gamma Fc Region Receptor II-b Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Low Affinity Immunoglobulin Gamma Fc Region Receptor II-b Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Low Affinity Immunoglobulin Gamma Fc Region Receptor II-b Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Low Affinity Immunoglobulin Gamma Fc Region Receptor II-b Demand Share Forecast, 2019-2026
9. North America Low Affinity Immunoglobulin Gamma Fc Region Receptor II-b Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Low Affinity Immunoglobulin Gamma Fc Region Receptor II-b Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Low Affinity Immunoglobulin Gamma Fc Region Receptor II-b Market Size and Volume Forecast by Application
9.4.1. Hospital
9.4.2. Clinic
9.4.3. Others
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Low Affinity Immunoglobulin Gamma Fc Region Receptor II-b Market Size and Volume Forecast by Type
9.7.1. XmAb-7195
9.7.2. BI-1206
9.7.3. MGD-010
9.7.4. SM-201
9.7.5. Others
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Low Affinity Immunoglobulin Gamma Fc Region Receptor II-b Demand Share Forecast, 2019-2026
10. Latin America Low Affinity Immunoglobulin Gamma Fc Region Receptor II-b Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Low Affinity Immunoglobulin Gamma Fc Region Receptor II-b Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Low Affinity Immunoglobulin Gamma Fc Region Receptor II-b Market Size and Volume Forecast by Application
10.4.1. Hospital
10.4.2. Clinic
10.4.3. Others
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Low Affinity Immunoglobulin Gamma Fc Region Receptor II-b Market Size and Volume Forecast by Type
10.7.1. XmAb-7195
10.7.2. BI-1206
10.7.3. MGD-010
10.7.4. SM-201
10.7.5. Others
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Low Affinity Immunoglobulin Gamma Fc Region Receptor II-b Demand Share Forecast, 2019-2026
11. Europe Low Affinity Immunoglobulin Gamma Fc Region Receptor II-b Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Low Affinity Immunoglobulin Gamma Fc Region Receptor II-b Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Low Affinity Immunoglobulin Gamma Fc Region Receptor II-b Market Size and Volume Forecast by Application
11.4.1. Hospital
11.4.2. Clinic
11.4.3. Others
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Low Affinity Immunoglobulin Gamma Fc Region Receptor II-b Market Size and Volume Forecast by Type
11.7.1. XmAb-7195
11.7.2. BI-1206
11.7.3. MGD-010
11.7.4. SM-201
11.7.5. Others
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Low Affinity Immunoglobulin Gamma Fc Region Receptor II-b Demand Share, 2019-2026
12. Asia Pacific Low Affinity Immunoglobulin Gamma Fc Region Receptor II-b Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Low Affinity Immunoglobulin Gamma Fc Region Receptor II-b Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Low Affinity Immunoglobulin Gamma Fc Region Receptor II-b Market Size and Volume Forecast by Application
12.4.1. Hospital
12.4.2. Clinic
12.4.3. Others
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Low Affinity Immunoglobulin Gamma Fc Region Receptor II-b Market Size and Volume Forecast by Type
12.7.1. XmAb-7195
12.7.2. BI-1206
12.7.3. MGD-010
12.7.4. SM-201
12.7.5. Others
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Low Affinity Immunoglobulin Gamma Fc Region Receptor II-b Demand Share, 2019-2026
13. Middle East & Africa Low Affinity Immunoglobulin Gamma Fc Region Receptor II-b Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Low Affinity Immunoglobulin Gamma Fc Region Receptor II-b Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Low Affinity Immunoglobulin Gamma Fc Region Receptor II-b Market Size and Volume Forecast by Application
13.4.1. Hospital
13.4.2. Clinic
13.4.3. Others
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Low Affinity Immunoglobulin Gamma Fc Region Receptor II-b Market Size and Volume Forecast by Type
13.7.1. XmAb-7195
13.7.2. BI-1206
13.7.3. MGD-010
13.7.4. SM-201
13.7.5. Others
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Low Affinity Immunoglobulin Gamma Fc Region Receptor II-b Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Low Affinity Immunoglobulin Gamma Fc Region Receptor II-b Market: Market Share Analysis
14.2. Low Affinity Immunoglobulin Gamma Fc Region Receptor II-b Distributors and Customers
14.3. Low Affinity Immunoglobulin Gamma Fc Region Receptor II-b Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. BioInvent International AB
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. MacroGenics, Inc.
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Shire Plc
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Xencor, Inc.
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. COMPANY5
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. COMPANY6
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. COMPANY7
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. COMPANY8
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. COMPANY9
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. COMPANY 10
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
